Welcome to our dedicated page for Cytek Biosciences SEC filings (Ticker: CTKB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cytek Biosciences, Inc. (Nasdaq: CTKB) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a public issuer on the Nasdaq Global Select Market. These documents help investors and analysts understand Cytek’s financial condition, operating results and governance as a cell analysis solutions company focused on Full Spectrum Profiling™ (FSP®) flow cytometry instruments, reagents and services.
Cytek submits Form 10-Q quarterly reports and Form 10-K annual reports, which include details on revenue from products, services and reagents, gross margins, operating expenses such as research and development, sales and marketing, and general and administrative costs, as well as information on cash and marketable securities. These filings also discuss risk factors, market conditions and other elements relevant to its analytical laboratory instrument manufacturing business.
The company also files Form 8-K current reports to disclose material events. Recent 8-K filings have covered quarterly financial results under Item 2.02 (Results of Operations and Financial Condition) and outcomes of the annual meeting of stockholders under Item 5.07, including votes on director elections, executive compensation and ratification of the independent registered public accounting firm.
In addition, investors can review exhibits attached to these filings, such as press releases furnished as Exhibit 99.1, which provide narrative context for the numbers reported. Over time, the filings record Cytek’s progress in areas such as recurring revenue growth from services and reagents, expansion of its installed instrument base and capital allocation decisions.
On Stock Titan, Cytek’s SEC filings are updated in near real time from the EDGAR system. AI-powered summaries highlight key points from lengthy 10-K and 10-Q reports, and help users quickly identify information on revenue composition, operating trends and risk disclosures. The page also makes it easier to locate Form 4 and other insider-related filings when available, supporting research into trading activity and governance practices at CTKB.
Cytek Biosciences, Inc. director and Chief Technology Officer Yan Ming reported several equity compensation transactions. On March 10, 2026, Ming received an employee stock option for 120,688 shares of common stock at an exercise price of $4.23 per share, vesting monthly over four years. He also received 227,535 Restricted Stock Units (RSUs), which vest over four years in specified tranches each May 18, August 18, November 18, and March 10 according to the award schedules.
Ming exercised previously granted RSUs covering a total of 25,400 shares of common stock. Of the resulting shares, 7,731 shares were withheld and surrendered to Cytek Biosciences at $4.23 per share to satisfy tax withholding obligations, and the remaining shares increased his direct common stock holdings. After these transactions, Ming directly owned 6,091,933 shares of common stock.
Cytek Biosciences director Michael Holder reported the vesting and exercise of restricted stock units into common shares as part of his equity compensation. On March 10, 2026, 2,908 RSUs converted into 2,908 shares of common stock at no cash cost, lifting his directly held common stock to 15,267 shares after the transaction.
Cytek Biosciences reports 2025 results and outlines its strategy as a leading cell analysis solutions provider built around its patented Full Spectrum Profiling (FSP) flow cytometry technology. The company sells Aurora, Northern Lights, Aurora Evo and Aurora CS instruments, reagents, software and services to pharma, biotech, CROs and academic labs worldwide.
Revenue was $201.5 million in 2025, up slightly from $200.5 million in 2024 and $193.0 million in 2023, while the net loss widened to $66.5 million from $6.0 million in 2024 and $12.1 million in 2023. Cash, cash equivalents, restricted cash and short-term investments totaled $261.5 million as of December 31, 2025.
The filing highlights new products such as the Aurora Evo system, Enhanced Small Particle detection, the Muse Micro analyzer and expansion of manufacturing in China and Singapore. Cytek emphasizes recurring consumables, software ecosystems like Cytek Cloud, clinical applications, global scale and an intellectual property portfolio protecting its FSP platform.
Cytek Biosciences reported modest 2025 revenue growth but a sharp drop in profitability and issued cautious 2026 guidance. Full-year 2025 revenue was $201.5 million, up 1% from 2024, with product revenue down and service revenue up.
GAAP gross margin fell to 52% from 55%, and operating expenses rose 10% to $144.8 million, driven mainly by higher general and administrative costs. The company posted a 2025 net loss of $66.5 million versus a $6.0 million loss in 2024, largely due to higher expenses and a non-cash deferred tax valuation allowance.
Adjusted EBITDA dropped to $5.0 million from $22.4 million, and cash and marketable securities declined to $261.5 million as of December 31, 2025, partly reflecting a $15.1 million share repurchase. For 2026, Cytek guides revenue to $205–$212 million, implying 2–5% growth.
Cytek Biosciences president and CEO Wenbin Jiang reported equity award activity involving restricted stock units and common shares. On February 18, 2026, 4,514 restricted stock units were converted into 4,514 shares of common stock at a price of 0.00 per share.
The Form 4 shows that 1,339 of these common shares, valued at 4.20 per share, were withheld and surrendered to Cytek Biosciences to cover tax withholding obligations tied to the vesting of this RSU award. After these transactions, Jiang directly held 5,359,827 shares of common stock.
Cytek Biosciences, Inc. director and Chief Technology Officer Yan Ming reported equity compensation activity involving restricted stock units (RSUs) and common stock. On February 18, 2026, 1,332 RSUs were converted into 1,332 shares of common stock at a stated price of $0.0000 per share.
On the same date, 395 shares of common stock at $4.20 per share were withheld and surrendered to Cytek to cover tax obligations arising from the RSU vesting, described as a tax-withholding disposition rather than an open-market sale. Following these transactions, Yan Ming directly held 6,074,264 common shares.
Cytek Biosciences, Inc. chief legal officer Valerie Barnett reported equity award activity involving restricted stock units and common shares. On February 18, 2026, 1,346 restricted stock units were exercised into 1,346 shares of common stock at a stated price of $0.00 per share.
On the same date, 525 common shares at $4.20 per share were withheld and surrendered to Cytek Biosciences to cover tax withholding obligations related to the vesting of this RSU award. After these transactions, Barnett directly held 116,462 shares of Cytek Biosciences common stock. The RSU award vests quarterly over four years, with an initial 4/48th tranche vesting on May 18, 2022, and 3/48th of the total shares vesting on each subsequent August 18, November 18, February 18, and May 18.
Cytek Biosciences, Inc. reported that it has issued a press release announcing its preliminary unaudited revenue for the fourth quarter and full year ended December 31, 2025. The company furnished this press release as Exhibit 99.1 to a current report, rather than treating it as formally filed financial information. The filing clarifies that the press release and related data are not incorporated into other securities law filings unless specifically referenced.
Cytek Biosciences (CTKB) chief technology officer and director reported multiple equity transactions on November 18, 2025 related to previously granted restricted stock units (RSUs). Several RSU tranches were converted into common stock, including blocks of 1,981, 7,363, 5,525 and 6,162 shares, reflecting ongoing vesting of long-term equity awards. To cover tax withholding from these vestings, a total of 4,? (aggregate of 483, 1,793, 1,346 and 1,501) shares were withheld and surrendered to the company at a price of $5.53 per share, rather than being sold on the open market. After these transactions, the insider directly beneficially owned 6,073,327 shares of Cytek common stock. The RSU grants continue to vest over multiple years on specified quarterly and annual dates.
Cytek Biosciences (CTKB) senior executive reports RSU vesting and share withholding transactions. On November 18, 2025, the SVP, Global Sales and Services converted multiple batches of restricted stock units (RSUs) into common stock and had shares withheld to cover taxes.
Form 4 data shows RSU exercises adding 1,536, 2,210, and 3,625 shares of common stock, with tax withholding sales of 393, 565, and 927 shares at $5.53 per share. After these transactions, the executive directly owned 28,902 shares of Cytek common stock.
The filing also reports remaining unvested or unsettled RSUs, with derivative holdings of 8,714, 20,628, and 48,338 RSUs, each tied to multi-year vesting schedules that allocate specific fractions of each award to vest on set dates in May, August, November, and March until fully vested.